Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Trump’s Election Impacts the Pharma Market: But for Good or Ill?

By Meg Snyder | November 9, 2016

After the world held its breath on Tuesday, November 8—awaiting the outcome of the U.S. presidential election—the resulting rippling effect has impacted a number of markets, the pharmaceutical industry included.

According to FirstWord Pharma, shares of the following European and Indian pharmaceutical companies rose with the announcement of the election of Donald Trump:

  • Novo Nordisk: 6.5 percent increase
  • Roche: 5 percent increase
  • Sanofi: 3 percent increase
  • Shire: 5 percent increase
  • Bayer: 3 percent increase
  • Hikma Pharmaceuticals: 7 percent increase

AstraZeneca, GlaxoSmithKline, and Novartis’s shares were also reported to have risen on Wednesday.

“BNP Paribas analysts noted that Trump’s election is ‘a positive for the (pharmaceuticals) sector, with the bulk of industry hostile legislation now off the agenda,'” FirstWord Pharma reports.

However, not everyone shares such an optimistic outlook for one of the world’s largest pharmaceutical markets.

The potential drug pricing mandates may seem like a thing of the past with Republicans having control of Congress, but some experts say that not only is the Reforming the Affordable Care Act (ACA) expected to be a “priority of the new Congress,” but drug pricing regulation “can be expected to be a piece of that reform.”

“Trump’s position is identical to Clinton’s—including price as another criterion to use in negotiations,” Terry Haines, Evercore ISI analyst, told investors.

Furthermore, legislation isn’t strictly about Trump’s agenda or intentions, as Congress writes the laws (and not the president). 

According to Fierce Biotech: “Jefferies analysts said U.S. pricing pressure and political reform ‘would remain a concern,’ but Trump’s win would be a relief for investors worried about a sea change in the U.S. system, which could have seen greater price controls from a Clinton administration.”

Beyond drug pricing regulations, global and internationally-based pharmaceutical companies have expressed concerns as to the potential reality of import tariffs and a ban on certain immigrant groups. These changes, which Trump spoke about during his campaign, would have impacts beyond the U.S. borders. 

Fierce Pharma, in their article titled “UPDATED: Pharma loves free trade. How will it get along with a protectionist President Trump?'” said:

In January, Trump told a crowd of 1,000 people in Farmington, NH, that Medicare could save $300 billion a year by negotiating discounts. “We don’t do it,” Trump said. “Why? Because of the drug companies.”

Trump favors another cost-saving move that has repeatedly failed in Congress, and could conceivably include it in ACA reform, too: drug reimportation, which would allow Americans to buy their prescription meds from other countries where prices are lower. Drugmakers are set against reimportation in the U.S.; after all, their sales have suffered from similar parallel trade within the EU.

Lead image photo credit: Gage Skidmore. 

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news! 


Filed Under: Drug Discovery

 

Related Articles Read More >

Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE